Company intelligence / Profile preview

GreyMatter Pharma

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

GreyMatter Pharma was a UK-based biotechnology company focused on developing novel formulations of existing drugs to treat rare diseases. The company's lead asset, GMP-102, is a long-acting, injectable formulation of dexamethasone designed to provide sustained therapeutic levels while potentially reducing the side effects associated with daily oral steroid use. In 2018, GreyMatter Pharma was acquired by Mallinckrodt Pharmaceuticals to bolster its autoimmune and rare disease pipeline. The acquisition centered on the development of GMP-102 for the treatment of Duchenne muscular dystrophy (DMD).

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

GRE2811

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Mallinckrodt

Beyond the preview

Go deeper on GreyMatter Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GreyMatter Pharma.

Explore the full profile